Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Novel MS Drug Offers Good Functional Outcomes
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Oligodendrocyte death results in immune-mediated CNS demyelination.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Spin-offs: Meet the structure specialists
Thrombotic microangiopathy associated with interferon beta.
Food and Drug Administration drug insert for Campath (alemtuzumab)
TGN1412: From Discovery to Disaster.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis

Pages